Uric Acid News and Research

RSS

BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011

BioCryst Pharmaceuticals, Inc. presented positive data from its two completed, randomized, double-blind, placebo-controlled Phase 2 studies of BCX4208 in patients with gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, U.K.

26 May 2011

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Ardea Biosciences, Inc. announced that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, UK.

26 May 2011

Patients with chronic heart failure can benefit from telemonitoring

Two trials presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology, will help to define the precise populations of patients with chronic heart failure in whom telemedical management delivers benefits.

23 May 2011

Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.

19 May 2011

BioCryst's BCX4208 study results in gout to be presented at EULAR meeting

BioCryst Pharmaceuticals, Inc. announced the presentation of clinical results related to BCX4208 for the treatment of gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, England.

22 Apr 2011

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron Pharmaceuticals, Inc. announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period.

28 Feb 2011

BioCryst reports net loss of $9.1M for fourth quarter 2010 vs. $15.2M net income for fourth quarter 2009

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2010.

10 Feb 2011

Research provides new clues for compulsive behavior, cognitive defects linked with LND

Research from the University of California, San Diego School of Medicine provides new clues for the compulsive behavior and cognitive defects associated with a rare childhood neurological disease called Lesch-Nyhan Disease.

29 Jan 2011

Uric acid levels linked to severe osteoarthritis

The amount of uric acid in one's joints may increase the likelihood of severe osteoarthritis, the most common form of arthritis worldwide, according to researchers at Duke University Medical Center.

19 Jan 2011

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol.

7 Jan 2011

BioCryst commences BCX4208/allopurinol combination Phase 2b study in gout patients

BioCryst Pharmaceuticals, Inc. announced the initiation of a Phase 2b study of BCX4208 as add-on therapy in gout patients who have not responded to allopurinol therapy alone.

22 Dec 2010

3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced that is has acquired worldwide rights of pegsiticase for all indications from EnzymeRx for a total consideration of US$6.25 million.

29 Nov 2010

Consumption of fructose-rich beverages can increase gout risk in women

Consumption of fructose-rich beverages, such as sugar-sweetened sodas and orange juice is associated with an increased risk of gout among women, although their contribution to the risk of gout in the population is likely modest because of the low incidence rate among women, according to a study that will appear in the November 24 print edition of JAMA.

11 Nov 2010

Researchers estimate increasing trend of hyperuricemia among adults, senior citizens

Hyperuricemia rates among the nation's adults and senior citizens remain substantially high, putting them at greater risk for developing gout, according to research presented at the Nov 2010, American College of Rheumatology Annual Scientific Meeting in Atlanta.

10 Nov 2010

Study demonstrates preventive effect of urate lowering therapy on cardiovascular mortality

The use of urate lowering therapy might successfully prevent death from cardiovascular disease in people with gout, according to research presented at the Nov 2010, American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Sugar-sweetened drinks can increase gout risk in women

Women who consume fructose-rich beverages, such as sugar-sweetened soft drinks and orange juice, are at an increased risk for gout, according to research presented at the Nov 2010, American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Uric Acid News and Research

BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Patients with chronic heart failure can benefit from telemonitoring

Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout

BioCryst's BCX4208 study results in gout to be presented at EULAR meeting

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

BioCryst reports net loss of $9.1M for fourth quarter 2010 vs. $15.2M net income for fourth quarter 2009

Research provides new clues for compulsive behavior, cognitive defects linked with LND

Uric acid levels linked to severe osteoarthritis

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

BioCryst commences BCX4208/allopurinol combination Phase 2b study in gout patients

3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million

Consumption of fructose-rich beverages can increase gout risk in women

Researchers estimate increasing trend of hyperuricemia among adults, senior citizens

Study demonstrates preventive effect of urate lowering therapy on cardiovascular mortality

Sugar-sweetened drinks can increase gout risk in women

BioCryst to present data on BCX4208 for gout at ACR Scientific Meeting

Caffeine intake increases risk for recurrent gout attacks

Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout

Hyperuricemia associated with increased risk for hypertension

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News